Close
4

Suanfarma Suanfarma

X

Company profile for ScalmiBio

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
ScalmiBio minimizes side-effects of oncology and immuno-oncology antibody therapeutics.ScalmiBio’s proprietary SHIELD platform technology converts therapeutic antibodies into prodrugs activated specifically within tumor.Adverse events related to presence of specific targets in normal tissues limit dosing and efficacy of antibody therapies and prevent potential targets from being evaluated in clinical trials. SHIELD technolog...
ScalmiBio minimizes side-effects of oncology and immuno-oncology antibody therapeutics.ScalmiBio’s proprietary SHIELD platform technology converts therapeutic antibodies into prodrugs activated specifically within tumor.Adverse events related to presence of specific targets in normal tissues limit dosing and efficacy of antibody therapies and prevent potential targets from being evaluated in clinical trials. SHIELD technology restricts activity of antibody therapeutics to the tumor microenvironment to limit side effects, enable higher therapeutic doses, and allow broader use of multi-target combination treatments.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
ScalmiBio
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
MBC Biolabs 733 Industrial Road San Carlos, CA 94070
Telephone
Telephone
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY